The researchers surveyed peer-reviewed literature published through mid-2024, searching PubMed, Google Scholar, ScienceDirect and Wiley Online Library for studies combining cannabidiol with terms covering sunscreens, antioxidants, inflammation, UV radiation and skin biology. From that search, 19 studies made the final cut: four review articles, nine in vitro experiments, three animal studies, one human clinical trial and two mixed-method investigations. The authors are candid about the limits of their approach. Because this was a narrative review rather than a systematic one, they did not apply PRISMA methodology or formal risk-of-bias assessment, and they acknowledge the search may have missed relevant work, particularly non-English publications.

The most striking findings concern CBD’s antioxidant chemistry. Structurally, the molecule shares features with vitamins E and C: phenolic hydroxyl groups attached to aromatic rings that can donate hydrogen atoms to reactive oxygen species and free radicals, interrupting the chain reactions that damage lipids, proteins and DNA. CBD is also highly lipophilic, allowing it to accumulate in cell membranes and stabilize them in a manner reminiscent of vitamin E. In rat experiments, chronic UVA and UVB exposure distorted keratinocyte membrane phospholipid metabolism, and topical CBD partially reversed those changes, downregulating harmful lysophosphatidylcholines and phospholipase A2 activity while upregulating protective phosphatidylethanolamines and phosphatidylserines. In human keratinocytes stressed with hydrogen peroxide or UVB, CBD reduced malondialdehyde and 4-hydroxynonenal, two well-established markers of lipid peroxidation, and modulated proteostasis networks governing protein folding and redox balance in ways that increased cell survival.

Beyond these direct chemical effects, CBD appears to manipulate the skin’s own antioxidant machinery. The review highlights its interaction with Nrf2, a redox-sensitive transcription factor often described as the master regulator of cytoprotective gene expression. Under normal conditions Nrf2 is held inactive by its nemesis Keap1, which tags it for destruction by the proteasome. Oxidative stress disrupts this pairing, freeing Nrf2 to enter the nucleus and switch on genes encoding superoxide dismutase, glutathione peroxidase and heme oxygenase 1. Intriguingly, keratinocyte studies suggest CBD is only a weak Nrf2 activator but a strong inhibitor of BACH1, a transcriptional repressor that works alongside Nrf2 to control heme oxygenase 1. This positions CBD as an Nrf2-independent booster of HMOX1 expression, encouraging keratinocyte differentiation and cytokeratin production, processes critical to maintaining a skin barrier that resists UV-induced DNA damage.

The anti-inflammatory story runs through a different set of molecular switches. CBD appears to be a major inhibitor of NFκB signaling, the central hub of the inflammatory response. Normally locked in the cytoplasm by its inhibitor IκB, NFκB is released when pro-inflammatory signals such as tumor necrosis factor alpha trigger IκB’s degradation, allowing the transcription factor to activate genes for cytokines, chemokines and adhesion molecules. UV irradiation drives inflammation through exactly this pathway, and in three-dimensional human keratinocyte cultures CBD counteracted it, restoring IκB levels and suppressing NFκB. CBD also dampened the NLRP3 inflammasome and the pro-inflammatory protein PGAM5, while full-spectrum CBD extract showed high-affinity inhibition of NLRP3 and TGF-β1 responses. In human skin fibroblasts, CBD elevated PPARγ, a nuclear receptor that represses inflammatory pathways, and in an acne study it significantly suppressed TNF-α, IL-1β and IL-6 in human sebocytes.

The endocannabinoid system adds yet another layer. CB2 receptors, found in immune and peripheral tissues including skin, can restrain pro-inflammatory cytokine release, and CBD’s modulation of CB2, along with its desensitization of TRPV1 channels activated by oxidative stress and its activation of adenosine A2A receptors, may collectively calm overactive immune responses in UV-damaged skin. One study of patients with psoriasis, atopic dermatitis and scarring found that a CBD-enriched ointment improved disease severity, quality of life, skin hydration and elasticity with no adverse effects. The review also flags a fascinating effect on melanocytes: CBD can activate p38 and p42/44 MAPK signaling and independently upregulate MITF, tyrosinase and related proteins, enhancing melanogenesis, the production of the pigment that naturally scatters and absorbs UV radiation. This raises potential applications for hypopigmented disorders and hints at melanin-mediated photoprotection.

But here is where the enthusiasm must be tempered, and the review is refreshingly blunt about it. Spectral analyses show that CBD absorbs UV light predominantly between roughly 220 and 280 nanometers, a range overlapping UVC, which is filtered out by the atmosphere, and only minimally touching the UVB band that sunscreens must block. In one comparative study, CBD showed the strongest cytoprotection against UVA-associated injury while cannabinol performed best against UVB, but neither CBD nor its relatives demonstrated direct photoprotective absorption at the wavelengths that matter. The authors emphasize that the observed cytoprotective effects should not be interpreted as sunscreen activity. CBD’s benefits, if real, would be indirect, working beneath the filter layer to help skin cells survive whatever radiation gets through.

Safety questions also complicate the picture. Most systematic safety data come from oral CBD, where randomized trials have identified increased risks of diarrhea, somnolence, decreased appetite and abnormal liver function tests, though the hepatic and sedation signals were concentrated in high-dose childhood epilepsy studies using drugs like clobazam and valproate. CBD is metabolized by CYP450 liver enzymes and can be a potent dose-dependent inhibitor of their activity, a concern that depends heavily on how much of a topical dose actually reaches the bloodstream. Evidence on that front is mixed: in a 17-day study of 46 healthy adults, CBD was detectable in blood after repeated use of three of five commercial topical products, though concentrations were far below those from oral or inhaled use and no cognitive or physiological effects appeared. Topical tolerability data remain thin and formulation-dependent, with patch-testing studies showing selected CBD products were non-irritating and non-sensitizing in healthy adults, while a transdermal gel trial saw application-site dryness, pain and one case of irritant contact dermatitis.

There is one tantalizing human data point. A small pilot randomized trial of nanoparticle-encapsulated topical CBD, involving just 19 participants, found less erythema on treated skin after UVA irradiation, along with reductions in epidermal hyperplasia and cellular stress and aging markers. But the study measured no SPF and included no active sunscreen comparator, so it cannot speak to whether CBD would add anything to a real product. The review also raises a subtle photochemical concern: when CBD oxidizes, it can form the cannabinoid quinone HU-331, which absorbs UV near 270 and 409 nanometers and has shown topoisomerase-II inhibition and endothelial-cell apoptosis induction in non-skin experimental systems. CBD and its hydroxyquinone have also generated reactive oxygen species during mouse liver microsomal metabolism. None of this demonstrates phototoxicity in human skin, but it marks genuine toxicologic uncertainties that demand study before CBD rides around in a sun-exposed bottle.

The regulatory landscape adds a final layer of complexity. In the United States, sunscreens are regulated as over-the-counter drugs, and only zinc oxide and titanium dioxide currently meet the FDA’s Generally Recognized as Safe and Effective standard, while the 2022 Modernization of Cosmetics Regulation Act has tightened scrutiny of cosmetic ingredients, with new 2026 legislation targeting full-spectrum CBD products specifically. Any manufacturer hoping to add CBD to a sunscreen would face registration, human safety substantiation and adverse event surveillance requirements. The review’s bottom line is measured: CBD may eventually earn a role as an adjunctive, non-filter component of photoprotective skincare, but the evidence base, dominated by in vitro and rodent work with enormous variability in models and doses, is nowhere near supporting claims of sun protection. Until standardized SPF, stability, photostability and human safety testing say otherwise, your sunscreen’s active ingredients should remain the ones with proven track records.

Subject of Research: Preclinical evidence on cannabidiol's effects against ultraviolet-induced skin damage and its potential as a sunscreen additive

Article Title: Cannabidiol and ultraviolet-induced skin damage: a narrative review of preclinical evidence and translational considerations for sunscreen additive development

Article References: Papadeas, G. G., Szeto, M. D., Reed, M. J., Paul, A., Runion, T. M., Anderson, J., & Dellavalle, R. P. (2026). Cannabidiol and ultraviolet-induced skin damage: a narrative review of preclinical evidence and translational considerations for sunscreen additive development. Archives of Dermatological Research, 318(1), Article 430. https://doi.org/10.1007/s00403-026-04888-x

Image Credits: AI Generated

DOI: 10.1007/s00403-026-04888-x

Keywords: cannabidiol, CBD, sunscreen, UV radiation, photoprotection, skin cancer, antioxidant, anti-inflammatory, keratinocytes, melanocytes, Nrf2, dermatology

At the center of the review is the endocannabinoid system, the body’s own lipid signaling network that cannabis hijacks so effectively. The system’s principal receptor, CB1, is one of the most densely expressed G-protein-coupled receptors in the mammalian brain, sitting presynaptically on axon terminals throughout the cortex and striatum. When endogenous cannabinoids such as anandamide and 2-arachidonoylglycerol are released, they travel backward across the synapse and dampen neurotransmitter release, acting as a short-range feedback brake on neural communication. Tetrahydrocannabinol, the main intoxicating component of cannabis, mimics these messengers but with far greater potency and duration, flooding the same circuits and disrupting the finely tuned timing they normally regulate. The review emphasizes that chronic exposure produces dysregulation of CB1 signaling and of the enzymes that synthesize and degrade endocannabinoids, and that this dysregulation maps directly onto the cortico-striatal circuits that govern reward learning, habit formation, and impulse control.

Equally important is the system’s role in stress biology. The endocannabinoid system modulates the hypothalamic-pituitary-adrenal axis and acts within the amygdala and prefrontal cortex to buffer the physiological response to stress. Withdrawal from cannabis, by contrast, is characterized by irritability, anxiety, sleep disturbance, and heightened stress reactivity, a picture consistent with a temporarily depleted endocannabinoid buffer. The review frames craving and relapse as failures of this buffer under load, which explains why stress is such a powerful trigger for relapse in people trying to cut down. This circuit-level account also explains why the disorder shares neurobiological ground with other addictions, while retaining features, such as the uniquely dense CB1 expression in cortical areas, that make it pharmacologically distinct.

Genetics adds a second, complementary layer of evidence. Large-scale genome-wide studies have identified polygenic vulnerability to cannabis use disorder involving loci such as FOXP2, NPTX1, CHRNA2, and PDE4B. Each of these genes points to a different biological process. FOXP2 is a transcription factor best known for its role in speech and motor circuit development, suggesting that neurodevelopmental pathways shape susceptibility. NPTX1 encodes a neuronal pentraxin involved in excitatory synapse maturation, implicating glutamatergic plasticity in the remodeling of reward circuits. CHRNA2, a nicotinic acetylcholine receptor subunit, hints at crosstalk between cholinergic signaling and cannabinoid systems, while PDE4B, a phosphodiesterase that degrades cyclic AMP, ties vulnerability to intracellular signaling and neuroimmune function. The authors stress that no single variant is decisive; rather, risk is distributed across many loci of small effect, which is precisely the kind of architecture that demands large datasets and careful stratification before it can be translated into the clinic.

The therapeutic section of the review is where the framework becomes concrete. Several mechanism-based candidates have now reached early-phase clinical trials, and although none has yet secured regulatory approval, the pattern of results offers proof of concept that targeting the endocannabinoid system can move clinical endpoints. Fatty acid amide hydrolase inhibitors, which block the enzyme that degrades anandamide, aim to amplify the brain’s own cannabinoid signaling in a controlled, spatially restricted way, in contrast to the global receptor activation produced by smoked cannabis. The logic is elegant: rather than flooding every synapse, the drugs strengthen endocannabinoid tone only where and when neurons are already releasing the messengers, potentially easing stress and withdrawal without producing intoxication.

Perhaps the most striking new class is the signaling-specific CB1 modulators, exemplified by the compound AEF0117. Traditional CB1 antagonists failed in the clinic years ago, largely because complete blockade of the receptor produced psychiatric side effects, including anxiety and depression risk. AEF0117 belongs to a generation of molecules designed to be more selective: it blocks the receptor’s signaling toward certain intracellular pathways while leaving others intact, aiming to suppress the reinforcing effects of THC without dismantling the receptor’s role in mood regulation. Early trials suggest this approach can attenuate the subjective reward of cannabis and reduce use, a result that, if confirmed in larger studies, would represent the first mechanism-based pharmacotherapy for the disorder. Alongside these targeted agents, cannabidiol has shown promise in reducing craving and reinforcement, and the review notes that selected repurposed drugs, developed for other indications, have also demonstrated proof-of-concept effects on withdrawal and use.

What elevates the review beyond a catalog of drug candidates is its insistence on heterogeneity. Cannabis use disorder is not one illness but a family of presentations that differ by biological sex, age of onset, psychiatric comorbidity, and patterns of consumption. Sex differences are particularly well documented: women appear to progress from casual use to disorder more rapidly, report different withdrawal profiles, and may respond differently to interventions, a pattern echoed in preclinical work showing sex-biased changes in gene expression networks after adolescent cannabis exposure in animal models. Comorbid anxiety, depression, and psychosis-spectrum symptoms further complicate the picture, since the same endocannabinoid circuits implicated in addiction also modulate mood and cognition. A treatment that works for a young man with heavy daily use and no comorbidities may fail for a woman in her thirties with anxiety-driven relapse, and the review argues that recognizing this is the precondition for precision medicine rather than an obstacle to it.

The precision psychiatry vision the authors sketch is therefore integrative by design. A patient’s endocannabinoid neurobiology, genetic risk profile, clinical presentation, and pattern of use would together inform which mechanism-based treatment is most likely to help. Someone with high stress-driven craving might be matched to an agent that boosts anandamide signaling; someone whose reinforcement circuitry is particularly THC-sensitive might receive a signaling-specific CB1 modulator; someone with strong glutamatergic genetic loading might benefit from interventions aimed at synaptic plasticity. This is not yet possible with current evidence, and the review is careful to frame it as a research agenda rather than a clinical protocol. But the building blocks, validated genetic loci, circuit-level neurobiology, and a growing pipeline of mechanism-specific compounds, now exist in the same place at the same time, which has not been true before.

The unmet clinical need gives this agenda urgency. Rising potency of cannabis products, expanding legalization, and growing global prevalence mean that the number of people with the disorder is climbing even as treatment options remain limited to behavioral therapies, which help many patients but leave a substantial fraction relapsing. The review, published open access with a permanent DOI and supported by funding from Taiwan’s National Science and Technology Council, makes the case that the field should stop treating cannabis use disorder as a monolithic problem awaiting a single blockbuster drug. Instead, it should be approached the way other chronic, heterogeneous conditions have been: by mapping the molecular subtypes, matching treatments to mechanisms, and letting biology, rather than trial-and-error, guide therapy. If that program succeeds, the era in which no approved medication exists for one of the world’s most common substance use disorders may finally be drawing to a close.

Subject of Research: Endocannabinoid neurobiology, genetic vulnerability, and emerging pharmacotherapies for cannabis use disorder

Article Title: Towards precision psychiatry for cannabis use disorder: integrating endocannabinoid neurobiology, genetics, and therapeutic innovation

Article References: Chan, L.-W., Chen, I., Yu, S., & Huang, Y.-C. (2026). Towards precision psychiatry for cannabis use disorder: integrating endocannabinoid neurobiology, genetics, and therapeutic innovation. Translational Psychiatry. https://doi.org/10.1038/s41398-026-04512-6

Image Credits: AI Generated

DOI: 10.1038/s41398-026-04512-6

Keywords: cannabis use disorder, endocannabinoid system, CB1 receptor, precision psychiatry, FAAH inhibitors, AEF0117, cannabidiol, genetics, addiction, withdrawal, Translational Psychiatry, pharmacotherapy

The scale of the problem is enormous. Roughly 50 million people sustain traumatic brain injuries annually, and the global economic burden exceeds 400 billion US dollars. Surgeons can relieve pressure and clinicians can manage symptoms with osmotic agents, diuretics, and glucocorticoids, but none of these supports repair of the injured tissue. The real killers are the secondary cascades that unfold over hours to days: rising intracranial pressure, cerebral edema, breakdown of the blood-brain barrier, ischemia, redox imbalance, and a self-reinforcing wave of neuroinflammation. Edema and inflammation feed each other. A leaky barrier lets immune cells and plasma flood into brain tissue, swelling activates resident microglia, and the inflammatory signals they release further destabilize the endothelial tight junctions that hold the barrier together. Breaking that loop is a central therapeutic goal.

Cannabidiol, or CBD, has long been an attractive candidate for exactly this job. It is anti-inflammatory, antioxidant, and non-intoxicating, and the team’s earlier work showed that CBD restores blood-brain barrier integrity after brain injury through the PGE2-EP2-cAMP pathway while also damping microglial activation. The obstacle has always been delivery. Because CBD is highly lipophilic, intraperitoneal injection sends much of the drug into adipose tissue rather than the brain. Oral dosing loses more than 70 percent of the compound to first-pass metabolism in the liver. Intravenous injection achieves full bioavailability but suffers from a short half-life and demands professional administration, an awkward constraint in acute care. None of the conventional routes keeps therapeutic levels of CBD parked at a contused cortex for the critical first days.

The researchers’ solution was a sponge made of gelatin methacryloyl, or GelMA, a photocrosslinkable hydrogel already used in drug delivery, ophthalmic therapy, and cardiac repair. The team synthesized GelMA by reacting gelatin with methacrylic anhydride, confirmed the modification with proton nuclear magnetic resonance spectroscopy and infrared spectroscopy, and screened twelve candidate formulations by varying the gelatin-to-anhydride ratio and ultraviolet crosslinking time. They judged each variant on swelling behavior, mass loss in simulated body fluid, and microstructure imaged by scanning electron microscopy. The winning formulation swelled only modestly, between 13 and 25 percent, retained a porous interconnected architecture, and fully degraded within five days under the tested conditions, a profile suited to a temporary implant that releases drug and then disappears.

Loading the sponge with CBD changed none of those material properties. Infrared spectra of the finished product showed the hydroxyl and aliphatic carbon-hydrogen stretching peaks characteristic of cannabidiol, while swelling and degradation curves remained essentially identical to the blank scaffold. Ultraperformance liquid chromatography measured encapsulation efficiencies between roughly 50 and 63 percent, with batch-to-batch variation below 3 percent and, remarkably, center-to-periphery drug ratios of almost exactly one, meaning the CBD was distributed evenly through each sponge. In a release assay, about 22 percent of the payload emerged in the first two hours, followed by a steady trickle that reached roughly 58 percent at 24 hours and 80 percent by 72 hours, precisely the sustained profile the early post-injury phase demands.

Safety testing came next, and it was thorough. Extracts of the sponge were applied to hippocampal neurons, astrocytes, and brain endothelial cells; viability remained high up to 5 micrograms per milliliter, defining a safe exposure window, while hemolysis assays with rat red blood cells showed rates below 5 percent. The team then implanted the sponges into rats subjected to a standardized weight-drop cortical contusion and tracked CBD with high-resolution liquid chromatography mass spectrometry. The pharmacokinetic contrast with conventional dosing was striking. After intraperitoneal injection, CBD in the injured cortex peaked at about 91 nanograms per gram and faded quickly. With the sponge, cortical concentrations reached about 251 nanograms per gram and remained detectable for the entire 48-hour observation window, while blood levels stayed low, an inversion of exposure that concentrates the drug at the lesion and spares the rest of the body. Serum chemistry and organ histology showed no treatment-related abnormalities.

The therapeutic results followed. Forty-eight hours after injury, rats receiving the medium and high doses of the CBD sponge scored significantly better on a standardized neurological deficit scale, traveled farther in open-field tests, and explored the open arms of an elevated plus maze more readily than injured controls, with mannitol and injected CBD providing comparable but generally weaker benefits. Under the microscope, the treated cortex retained orderly neuronal architecture and intact Nissl bodies, showed fewer TUNEL-positive apoptotic cells, and released lower levels of neuron-specific enolase and S-100 calcium-binding protein beta, two canonical markers of neural damage. The blank sponge alone conferred little benefit, indicating that sustained CBD release, not the scaffold itself, drove the protection.

Mechanistically, the study points to the blood-brain barrier and the water channel aquaporin-4. Treated rats had less brain water content and far less Evans blue dye leaking across the barrier, alongside restored expression of the tight junction proteins ZO-1, occludin, and claudin-5. Molecular docking predicted that CBD binds aquaporin-4 with a binding energy of minus 6.7 kilocalories per mole, and surface plasmon resonance confirmed a measurable micromolar interaction with a dissociation constant of 56.6 micromolar. After injury, aquaporin-4 shifted away from vascular endothelial structures and toward reactive, GFAP-positive astrocytes; the sponge reversed that redistribution, reduced astrocytic overactivation, and preserved endothelial markers. On the inflammatory front, the treatment lowered interleukin-6, interleukin-1 beta, and tumor necrosis factor-alpha, raised the anti-inflammatory interleukin-10, and calmed Iba-1-stained microglia. RNA sequencing of the injured cortex identified nearly 800 differentially expressed genes and pointed to dampened NF-kappaB and TNF signaling alongside enhanced PI3K-Akt survival signaling, changes the authors confirmed by Western blot and quantitative PCR.

The authors are careful about the limits of their work. The study captured only the acute, two-day phase, leaving long-term cognitive and behavioral recovery untested, and the local and injected CBD regimens were not matched for dose or exposure, so some benefits may reflect the delivery platform rather than the drug alone. No formal power calculation was performed, and the transcriptomic analysis omitted the blank-sponge and injected-CBD groups. Even so, the concept is compelling: a cheap, photocrosslinkable gelatin sponge that turns a one-shot drug depot into a 48-hour local infusion, right where edema and inflammation are born. If future studies with exposure-matched controls and longer follow-up bear out these results, the humble gelatin sponge could become a serious contender in the long-delayed search for the first true neuroprotective therapy for traumatic brain injury.

Subject of Research: Local delivery of cannabidiol using a GelMA hydrogel sponge to treat cerebral edema and neuroinflammation after traumatic brain injury

Article Title: In situ delivery of cannabidiol-loaded GelMA sponge attenuates cerebral edema and neuroinflammation in traumatic brain injury

Article References: Li, H., Luo, X., Cao, Y., Jiang, H., Guo, Z., Zhu, Y., Zhang, L., Li, Z., Li, J., Wu, H., & Li, P. (2026). In situ delivery of cannabidiol-loaded GelMA sponge attenuates cerebral edema and neuroinflammation in traumatic brain injury. Materials Today Bio, 41, Article 103721. https://doi.org/10.1016/j.mtbio.2026.103721

Image Credits: AI Generated

DOI: 10.1016/j.mtbio.2026.103721

Keywords: traumatic brain injury, cannabidiol, GelMA hydrogel, drug delivery, cerebral edema, blood-brain barrier, neuroinflammation, aquaporin-4, microglia, NF-kappaB signaling, biomaterials, rat model

The endocannabinoid system consists of lipid signaling molecules called endocannabinoids, principally anandamide and 2-arachidonoylglycerol, along with their G-protein-coupled receptors, CB1 and CB2, and the enzymes that synthesize and degrade these messengers. CB1 receptors are abundant on nociceptive sensory neurons in the dorsal root ganglia, where their activation dampens the release of pain-transmitting neurotransmitters. CB2 receptors are found predominantly on immune cells, including mast cells and macrophages, and their engagement suppresses the release of proinflammatory cytokines. Beyond these classic receptors, cannabinoids also interact with non-cannabinoid targets such as the ion channel TRPV1, the nuclear receptor PPAR-gamma, serotonin receptors, and orphan G-protein-coupled receptors like GPR18 and GPR55, giving the system an unusually broad pharmacological reach.

What makes this system particularly relevant to endometriosis is that it is not merely a bystander. Human studies have documented elevated systemic levels of endocannabinoids and related mediators across the menstrual cycle in women with endometriosis, and cannabinoid receptor expression has been detected directly in endometriotic lesions. Animal work has shown that the CB1 receptor contributes to the development of ectopic lesions in a mouse model of the disease, while other studies report decreased expression of cannabinoid receptors in the eutopic and ectopic endometrium of patients with adenomyosis, a closely related condition. In other words, the endocannabinoid machinery appears to be rewired in diseased tissue, positioning it as both a marker and a potential driver of pathology.

The review organizes the therapeutic logic of cannabinoids around three mechanistic pillars: inflammation, nociceptive signaling, and lesion proliferation. On the inflammatory front, endometriosis is characterized by a peritoneal environment awash with proinflammatory cytokines, activated macrophages, and degranulating mast cells, all of which sensitize nearby nerve fibers. Cannabinoids attenuate this cascade by inhibiting proinflammatory cytokine signaling and reducing the release of inflammatory mediators from mast cells and peritoneal macrophages. Cannabidiol, the non-psychoactive phytocannabinoid, has been shown in molecular studies to blunt the inflammatory and oxidative processes associated with endometriosis, and CB2-selective agonists reduce cytokine release in blood mononuclear cells. Because neurogenic inflammation, driven by mast cells and nerve fiber interactions, is increasingly recognized as central to endometriosis pain, this immunomodulatory action is a plausible route to symptom control.

The second pillar concerns direct suppression of pain signaling and sensitization. Endometriosis-associated pain involves peripheral, central, and cross-sensitization, in which repeated nociceptive input from pelvic lesions amplifies responses throughout the nervous system, sometimes producing comorbid pain syndromes such as fibromyalgia. Cannabinoids counter this at multiple levels. Activation of peripheral CB1 and CB2 receptors suppresses the maintenance of inflammatory nociception, and genetic studies indicate that cannabinoid analgesia is mediated largely through peripheral type 1 cannabinoid receptors on nociceptors. Cannabidiol acts on TRPV1 signaling pathways in cultured dorsal root ganglion neurons, and CB1 receptor agonists can prevent nerve growth factor-induced sensitization of TRPV1 in sensory neurons, a mechanism directly relevant to the elevated TRPV1 expression observed in the dorsal root ganglia of rats with endometriosis and in peritoneal endometriotic foci of women with chronic pelvic pain.

The third pillar is antiproliferative. Endometriotic lesions behave somewhat like benign tumors, proliferating, invading, and recruiting new blood vessels. Synthetic cannabinoid agonists such as WIN 55212-2 have been shown to target proliferation, angiogenesis, and apoptosis via MAPK/AKT signaling in human endometriotic cell lines and in a murine model of the disease. Cannabinoid agonists exert antiproliferative effects on deep infiltrating endometriosis tissue, and cannabidiol demonstrated anti-inflammatory, antioxidative, and antiangiogenic effects in an experimental rat model. Natural delta-9-tetrahydrocannabinol has even shown disease-modifying effects on endometriosis-associated pain in animal studies, suggesting that cannabinoids might not only mask symptoms but also slow lesion growth, a property that no current medical therapy can claim.

The mechanistic enthusiasm is mirrored by striking epidemiological reality. Surveys from Australia, New Zealand, Canada, Germany, and the United States consistently show that large numbers of women with endometriosis are already using cannabis, often illicitly or without medical supervision, to self-manage their pain, and many report perceived effectiveness. A national survey of Australian women identified cannabis as a common self-management strategy, and international cross-sectional research conducted during the COVID-19 pandemic documented continued and in some cases increased use. National survey data further indicate substantial willingness among women to try cannabis for gynecological conditions. This grassroots adoption has outpaced the clinical evidence, creating a situation in which patients are experimenting on themselves with products of variable composition and dosing, while physicians lack the trial data needed to guide them.

The review’s authors argue that this gap makes properly controlled clinical trials an urgent priority. Several challenges stand in the way. Cannabinoid pharmacology is complicated by the entourage effect, in which combinations of phytocannabinoids and terpenes may produce effects different from isolated compounds, and by the psychoactivity of THC, which limits tolerable doses. However, recent structural and pharmacological advances are opening new doors. The discovery of a cryptic pocket in the CB1 receptor that drives peripheral and functional selectivity suggests it may be possible to design analgesics that activate pain-relieving pathways without central psychoactive effects. Separately, the sodium channel Nav1.8 has been identified as an analgesic target for non-psychotomimetic phytocannabinoids, offering another route to pain relief without intoxication. Such advances could yield peripherally restricted cannabinoid medicines tailored to endometriosis, an approach that would sidestep many of the regulatory and tolerability obstacles that have hampered the field.

There is also an opioid angle that gives the research public-health urgency. Women with endometriosis are frequently prescribed opioids for their pain, and cohort studies in US administrative claims data have documented chronic opioid use and its complication risks in this population. Cannabinoids interact with the opioid system, and a growing body of preclinical and clinical evidence supports an opioid-sparing effect of cannabinoids for analgesia. Because cannabinoid receptor expression has been detected in endometriotic lesions of women with the disease, some researchers have proposed cannabinoid-based approaches as an alternative to opioid-based pain medication. If clinical trials confirm meaningful analgesia, cannabinoids could help reduce opioid exposure in a patient population disproportionately affected by long-term opioid therapy and its attendant risks of dependence and hyperalgesia.

Cautious optimism is the appropriate stance. The evidence base remains dominated by in vitro studies and animal models, and human interventional data are still sparse, while the endocannabinoid system also plays fundamental roles in endometrial and placental biology, raising questions about reproductive safety that trials must address. Yet the convergence of epidemiological demand, mechanistic plausibility across inflammation, nociception, and proliferation, and emerging medicinal chemistry that promises non-psychoactive, peripherally targeted drugs makes the endocannabinoid system one of the most compelling therapeutic frontiers in endometriosis research. As the Wayne State team concludes, the system’s regulation of nociception, inflammation, and lesion growth warrants rigorous clinical evaluation, and for the millions of women whose pain has outlasted every existing therapy, that evaluation cannot come soon enough.

Subject of Research: The role of the endocannabinoid system in the mechanisms and treatment of endometriosis-associated pain

Article Title: The Endocannabinoid System in Endometriosis-Associated Pain: Mechanisms, Molecular Targets, and Therapeutic Implications

Article References: Stone, A. M., Veltre, V. L., Camp, O. G., Biernat, M. M., & Abu-Soud, H. M. (2026). The Endocannabinoid System in Endometriosis-Associated Pain: Mechanisms, Molecular Targets, and Therapeutic Implications. Reproductive Sciences. https://doi.org/10.1007/s43032-026-02201-9

Image Credits: AI Generated

DOI: 10.1007/s43032-026-02201-9

Keywords: endometriosis, endocannabinoid system, cannabinoids, cannabidiol, chronic pelvic pain, CB1 receptor, CB2 receptor, inflammation, nociception, TRPV1, lesion proliferation, clinical trials

The team worked with male C57BL/6J mice, giving them purified CBD intraperitoneally at 0.2, 10 or 20 milligrams per kilogram of body weight. One group received the compound for just two days, representing short-term or sporadic use, while another group was treated daily for 28 days to mimic chronic exposure. Vehicle-treated controls received the same saline and Tween 80 solution without the active compound. The researchers then measured three classic pro-inflammatory cytokines in plasma, interleukin-1 beta, interleukin-6 and tumour necrosis factor alpha, using ELISA assays, and performed RNA sequencing on the liver and spleen to capture the full transcriptional response in each organ. Sequencing produced an average of 32.4 million raw reads per liver sample, with roughly three quarters of filtered reads uniquely mapped to the mouse reference genome GRCm39.

The cytokine results revealed a striking temporal split. After only two days of treatment, CBD significantly reduced IL-1β across all doses, with concentrations falling from about 69.7 picograms per millilitre in controls to between 49 and 57 picograms per millilitre, an 18 to 30 percent drop. TNF-α fell even harder, declining by roughly 20 to 45 percent in a dose-dependent fashion. IL-6, however, barely moved during this early window. Its decline emerged only during prolonged treatment: by day 14, IL-6 was significantly reduced at every dose, and by day 28 the two higher doses had driven levels down by approximately 40 to 45 percent, from 45.3 to under 29 picograms per millilitre. TNF-α remained suppressed at day 28 as well, suggesting that some anti-inflammatory effects persist while others fade or shift character over time.

The liver, the organ that also handles CBD clearance, turned out to be the epicentre of transcriptional change. Short-term high-dose treatment altered 526 genes, of which nearly 90 percent were upregulated, and enrichment analysis pointed squarely at mitochondrial energy metabolism: oxidative phosphorylation, electron transport chain activity, ATP synthesis and ribosome biogenesis were all prominently represented. The lowest short-term dose affected 116 genes linked to steroid and mineralocorticoid biosynthesis, tissue morphogenesis and lipid transport, while the intermediate dose touched only 11 genes, a reminder that cannabinoids often produce nonlinear, dose-dependent effects. After 28 days, the picture changed again. Long-term treatment altered between 104 and 404 genes depending on dose, with enrichment shifting toward fatty acid and eicosanoid metabolism, arachidonic acid pathways, and, at the highest dose, circadian rhythm regulation including the molecular clock gene Nr1d1, which encodes the nuclear receptor REV-ERBα.

That circadian finding may be one of the most intriguing threads in the study. REV-ERBα is a core component of the cellular clock, and previous work has shown it directly modulates innate immune responses and cytokine production. Immune function in general runs on a diurnal rhythm, with leukocyte trafficking and cytokine secretion varying robustly across the day. The fact that prolonged high-dose CBD enriched circadian and rhythmic process categories, while simultaneously downregulating genes involved in glucocorticoid receptor signalling and responses to nutritional and metabolic stimuli, suggests the compound may be tapping into the deep regulatory circuitry that connects clocks, stress hormones and metabolism rather than merely dampening inflammatory pathways one by one.

Perhaps the most counterintuitive result came at the highest long-term dose, where upregulated liver genes were enriched for innate immune and inflammatory processes, including antimicrobial humoral immunity, interleukin-1-mediated signaling and neutrophil chemotaxis. On its face, this looks like inflammation ramping up. Yet circulating cytokines remained reduced at the same time. The authors interpret this as evidence that transcriptional activation of immune-related pathways does not necessarily translate into systemic inflammatory output; it may instead reflect adaptive regulatory reprogramming. This distinction matters, because it separates genuine immunosuppression from a subtler recalibration of immune-metabolic networks, and it aligns with the well-established principle that cellular metabolism and immune cell behaviour are tightly intertwined.

The spleen told a very different story. Despite being the body’s central blood-filtering lymphoid organ, packed with T cells, B cells, macrophages and dendritic cells, and rich in CB2 cannabinoid receptors, the spleen showed remarkably modest transcriptional responses. Short-term treatment at the highest dose altered 40 genes, 38 of them downregulated, with the only significant enrichment involving lipid modification processes. Long-term treatment changed just two to four genes depending on dose. This muted splenic response, set against the liver’s dramatic remodeling, led the authors to a provocative conclusion: the systemic cytokine changes observed in blood are probably not driven primarily by classical immune organs, but rather by indirect regulation flowing from metabolically active tissues, with the liver acting as a kind of immunometabolic command centre.

Mechanistically, the findings fit CBD’s known multimodal pharmacology. Unlike THC, CBD has low affinity for the canonical CB1 and CB2 cannabinoid receptors and instead influences a scatter of molecular targets, including PPARγ, TRPV1 channels, adenosine signalling and redox-sensitive pathways, while inhibiting the transcription factor NF-κB, a master regulator of TNF-α and IL-1β expression. The early cytokine drops are consistent with NF-κB inhibition, while the delayed IL-6 decline may reflect a gradual attenuation of upstream inflammatory stimuli, since IL-6 production often sits downstream of IL-1β and TNF-α cascades. The lipid metabolism enrichment during long-term treatment echoes recent human cell studies showing that CBD can switch lipid mediator production toward inflammation-resolving species, and the authors’ own prior work found similar circadian and metabolic signatures in the kidneys of CBD-treated mice.

The study’s temporal dimension carries practical weight. Short-term exposure produced acute bioenergetic and stress-related transcriptional responses alongside rapid IL-1β and TNF-α suppression, whereas prolonged exposure shifted toward lipid handling, circadian regulation and broader immunometabolic pathways, with sustained IL-6 reduction. CBD’s high lipophilicity means it accumulates in lipid-rich, well-perfused tissues over repeated dosing, so the biological response evolves rather than simply intensifying. For anyone interpreting CBD experiments, or weighing its therapeutic potential, duration of exposure may matter as much as dose, and the two interact in ways that a single time point cannot capture.

The authors are careful about limitations. The pathways identified by RNA sequencing were not validated with targeted functional assays, bulk transcriptomics cannot distinguish changes within individual cell types from shifts in cellular composition, and only male mice were studied, leaving open the question of sex-dependent responses in endocannabinoid signalling and immunity. Still, the integrated picture is compelling: CBD lowered circulating pro-inflammatory cytokines while triggering strong, dose- and time-dependent transcriptional reprogramming in the liver and only limited changes in the spleen. Rather than acting as a blunt immunosuppressant, the compound appears to coordinate adjustments across mitochondrial bioenergetics, lipid metabolism, glucocorticoid pathways and circadian regulators such as REV-ERBα, nudging immune-metabolic networks toward balance. If that model holds up in functional studies and in both sexes, it could reshape how researchers think about CBD’s promise in inflammatory, autoimmune and metabolic disease.

Subject of Research: Effects of cannabidiol on systemic cytokines and liver and spleen transcriptomes in male mice

Article Title: Cannabidiol (CBD) differentially shapes systemic cytokines and transcriptomic profiles in the liver and spleen: insights from a male mouse model

Article References: Żurowski, J., Ocłoń, E., Jasielczuk, I., Szmatoła, T., Mizera-Szpilka, K., Semik-Gurgul, E., Sawicki, S., & Gurgul, A. (2026). Cannabidiol (CBD) differentially shapes systemic cytokines and transcriptomic profiles in the liver and spleen: insights from a male mouse model. Molecular Genetics and Genomics, 301(1), Article 200. https://doi.org/10.1007/s00438-026-02525-w

Image Credits: AI Generated

DOI: 10.1007/s00438-026-02525-w

Keywords: cannabidiol, CBD, cytokines, transcriptomics, liver, spleen, immunometabolism, NF-kappaB, circadian rhythm, REV-ERBalpha, mouse model, inflammation

The study, published in the Journal of Molecular Medicine, was led by Alejandro Silva-Palacios, Alejandra María Zúñiga-Muñoz, and Cecilia Zazueta of the National Institute of Cardiology Ignacio Chávez in Mexico City, together with collaborators at the National Autonomous University of Mexico and Tecnológico de Monterrey. The researchers set out to test whether cannabidiol, commonly abbreviated as CBD, could protect the heart in an animal model that closely mimics the human condition. They induced HFpEF in mice by combining a high-fat diet with L-NAME, a compound that inhibits nitric oxide synthesis and drives the nitrosative stress considered central to the disease. Over eight weeks, the animals developed the hallmark features of HFpEF: cardiac fibrosis, diastolic dysfunction, and systemic metabolic and inflammatory disturbances. CBD was then administered subcutaneously every three days, a dosing interval chosen to maintain sustained exposure to the compound.

The results were nuanced but striking. CBD did not shrink the enlarged, hypertrophied hearts of the diseased animals; cardiac hypertrophy persisted despite treatment. However, the compound produced meaningful improvements where they mattered most for HFpEF patients. Treated animals showed reduced cardiac fibrosis, the stiffening scar tissue that prevents the heart muscle from relaxing, and their diastolic function improved measurably. The researchers assessed hemodynamic performance using invasive pressure-volume loop analysis, the gold standard for evaluating how the ventricle fills and ejects blood, and complemented these measurements with histological examination and markers of oxidative stress. The improvement in filling dynamics, rather than pumping strength, is precisely the kind of benefit that HFpEF patients need, since their hearts fail not because they pump too weakly but because they cannot relax enough to refill.

To understand how CBD achieved these effects, the team turned their attention to cellular senescence, the state in which cells stop dividing but refuse to die, instead lingering in tissues and secreting a toxic cocktail of inflammatory molecules. This senescence-associated secretory phenotype, or SASP, has emerged as a key driver of age-related diseases, and growing evidence links it to heart failure. In the HFpEF mice, senescent cells had accumulated in the heart, and circulating cytokine levels were elevated, consistent with a body-wide SASP-driven inflammatory state. CBD treatment markedly reduced the accumulation of these senescent cells and lowered systemic cytokine levels. The finding suggests that CBD may act as a partial senotherapeutic, clearing or calming the aged cells that fuel chronic inflammation in the failing heart.

The second major target was the NLRP3 inflammasome, a molecular machine inside immune and cardiac cells that, when activated, triggers caspase-1 and the release of potent proinflammatory cytokines such as interleukin-1 beta. NLRP3 activation has been implicated in cardiac remodeling, pulmonary artery changes, and general inflammation in HFpEF, and pharmacological inhibitors of this inflammasome have already shown benefit in mouse models of the disease. In the current study, CBD suppressed the NLRP3-mediated proinflammatory state, adding to a growing body of evidence that the compound can dampen inflammasome signaling. Previous work had shown that CBD inhibits NLRP3 activation in human monocytes through modulation of the P2X7 receptor, and that cannabinoids can attenuate cytokine storms driven by inflammasome pathways. The new findings extend this anti-inflammatory repertoire into the HFpEF setting.

Perhaps the most novel contribution of the study lies in its third focus: the mitochondria-endoplasmic reticulum contact sites, abbreviated MERCSs. These are microscopic junctions where the membranes of mitochondria, the cell’s power plants, and the endoplasmic reticulum, its protein-folding and calcium-storage factory, come into close apposition. At these contact points, the two organelles exchange calcium, lipids, and stress signals, coordinating everything from energy metabolism to cell death decisions. When MERCSs become excessive or disorganized, calcium overload and mitochondrial destabilization can activate the NLRP3 inflammasome, linking organelle architecture directly to inflammation. Using transmission electron microscopy, immunofluorescence, and RT-qPCR, the researchers found that in HFpEF the integrity of these contact sites was compromised, and that CBD treatment preserved inter-organelle distance and MERCSs structure.

This is the first demonstration, according to the authors, that CBD modulates MERCSs communication to regulate senescence and inflammation in HFpEF. The finding ties together threads that had previously run in parallel. Earlier work from the same group had shown that senotherapy in obese rats could act through a MERCSs/Nrf2 interaction, and other studies had established that disrupted sarcoplasmic reticulum-mitochondrial contacts underlie contractile dysfunction in atrial fibrillation, while enhanced tethering can trigger adaptive cardiac remodeling. In diabetes, hyperglycemia-driven promotion of mitochondria-associated endoplasmic reticulum membranes contributes to cardiomyopathy, and in aged hearts, defective calcium exchange between these organelles impairs function. By preserving the geometry of these junctions, CBD appears to prevent the calcium mishandling and mitochondrial stress that ignite inflammasome activation, thereby interrupting a vicious cycle in which organelle damage feeds inflammation, which in turn accelerates cellular aging.

The implications extend beyond the laboratory. HFpEF accounts for roughly half of all heart failure cases, and its burden is growing with the obesity and diabetes epidemics. Current treatment options remain limited, with recent trials of sodium-glucose cotransporter-2 inhibitors offering only partial benefit, and one such agent, empagliflozin, has been shown to protect against HFpEF partly by inhibiting a senescence-associated signaling axis. Pharmacological clearance of senescent cells has independently been shown to reduce inflammation, endothelial damage, and cardiac fibrosis in HFpEF models. The convergence of these findings suggests that targeting the biology of aging itself—senescent cells, their secretory products, and the organelle networks that control cellular stress—may be a viable therapeutic strategy for a disease that has defied conventional approaches.

CBD brings its own compelling profile to this strategy. Unlike tetrahydrocannabinol, it does not produce intoxication, and it has already been approved for certain forms of epilepsy, giving clinicians experience with its safety profile. Prior animal studies have shown that CBD attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory signaling in diabetic cardiomyopathy, prevents heart failure dysfunction through preservation of mitochondrial function and calcium handling, and promotes cardiomyocyte proliferation after myocardial infarction. A clinical trial, the ARCHER study, is currently evaluating CBD’s impact on myocardial recovery in patients with acute myocarditis. The new HFpEF findings add another potential indication to this expanding list, though the authors caution that the signaling pathways connecting MERCSs preservation to reduced senescence and inflammation still need to be fully characterized.

Important questions remain before CBD can be considered a treatment for HFpEF. The study was conducted in mice, and the dose, route, and timing of administration would need careful translation to humans. The failure to reduce hypertrophy suggests that CBD addresses some but not all of the disease’s pathological drivers, and it is unclear whether starting treatment earlier or later would change the outcome. Nevertheless, by identifying premature senescence, NLRP3-mediated inflammation, and MERCSs integrity as linked, druggable targets in HFpEF, the Mexican team has offered both a mechanistic explanation for CBD’s cardioprotective effects and a roadmap for the next generation of experiments. For a disease that affects millions and has resisted nearly every therapeutic attempt, the idea that a well-tolerated plant-derived compound might restore youthful communication between a cell’s organelles and quiet the inflammatory noise of aging tissue is a prospect worth watching closely.

Subject of Research: The cardioprotective effects of cannabidiol in heart failure with preserved ejection fraction through modulation of cellular senescence, NLRP3 inflammation, and mitochondria-endoplasmic reticulum contact sites.

Article Title: Prospective associations of premature senescence, inflammation, and MERCSs in the cardioprotective effect of CBD in HFpEF

Article References: Silva-Palacios, A., Zúñiga-Muñoz, A. M., Soria-Castro, E., Álvarez-León, E., García-Niño, W. R., Navarrete-Anastasio, G., Raza, D., Aparicio-Trejo, O. E., Ramírez-Carreto, R. J., Salas-Venegas, V., Chavarría, A., Maldonado-Ruíz, R. A., Alves-Figueiredo, H., García-Rivas, G., & Zazueta, C. (2026). Prospective associations of premature senescence, inflammation, and MERCSs in the cardioprotective effect of CBD in HFpEF. Journal of Molecular Medicine, 104(1), Article 109. https://doi.org/10.1007/s00109-026-02715-4

Image Credits: AI Generated

DOI: 10.1007/s00109-026-02715-4

Keywords: heart failure, HFpEF, cannabidiol, cellular senescence, SASP, NLRP3 inflammasome, MERCSs, mitochondria, endoplasmic reticulum, cardiac fibrosis, diastolic dysfunction, inflammation

CINP is a major dose-limiting toxicity of some of the most widely used chemotherapy classes, including platinum drugs such as oxaliplatin and cisplatin, taxanes like paclitaxel, and vinca alkaloids. Estimates suggest that between 30 and 60 percent of patients receiving certain regimens develop the condition. Clinically, it presents as spontaneous and evoked persistent pain, frequently manifesting as mechanical and thermal allodynia—pain triggered by normally harmless stimuli such as light touch or mild warmth. But the damage does not stop at pain. Patients often experience additional sensory disturbances, motor dysfunction, cognitive impairment, and affective disorders, all of which severely compromise quality of life and, in some cases, force oncologists to reduce or discontinue life-prolonging treatment.

The therapeutic landscape is bleak. According to the review, current preventive measures are essentially lacking, and the treatments that do exist are largely palliative, managing symptoms without addressing the underlying neurobiological mechanisms. Standard analgesics, including some antidepressants and anticonvulsants borrowed from other neuropathic pain conditions, offer incomplete relief for many patients. This gap has driven researchers to look for targets that act on the biology of the damaged nerves themselves—and the endocannabinoid system has emerged as one of the most intriguing candidates.

The endocannabinoid system is the body’s endogenous modulator of pain processing, active under both physiological and pathological conditions. It comprises two principal endogenous ligands, anandamide and 2-arachidonoylglycerol (2-AG), the enzymes that synthesize and metabolize them—including fatty acid amide hydrolase (FAAH), monoacylglycerol lipase (MGL), diacylglycerol lipases (DAGL), and N-acyl phosphatidylethanolamine phospholipase D (NAPE-PLD)—fatty acid-binding proteins and membrane transporters that shuttle the ligands, and two main receptors, cannabinoid receptor type 1 (CB1) and type 2 (CB2). CB1 receptors are densely expressed at central and peripheral sites along the pain pathway, while CB2 receptors are prominent on immune cells and become upregulated in injury states. Together, these components exert multifaceted regulatory effects at the periphery, in the spinal cord, and in the brain.

What makes the endocannabinoid system particularly interesting in the context of CINP is that experimental models show dynamic changes in its components after chemotherapy exposure. Rather than being a static bystander, endogenous cannabinoid signaling appears to become dysregulated as neuropathy develops, suggesting that restoring or enhancing this signaling could be therapeutically useful. Indeed, the review documents that direct or indirect modulation of cannabinoid receptors has been shown to both prevent and mitigate behavioral indicators of pain in CINP models. Strategies include direct agonists such as arachidonyl-2′-chloroethylamide (ACEA), inhibitors of the enzymes that break down anandamide and 2-AG, positive allosteric modulators that fine-tune receptor activity, and interventions targeting the endocannabinoid membrane transporter. Indirect approaches are especially attractive because they amplify endocannabinoid signaling only where and when it is naturally produced, potentially reducing the central side effects—such as psychoactivity—that limit direct CB1 agonism.

Beyond the endocannabinoid system itself, preclinical studies have explored the analgesic and neuroprotective properties of phytocannabinoids derived from the cannabis plant, primarily Δ⁹-tetrahydrocannabinol (THC) and cannabidiol (CBD). The evidence indicates that both compounds, administered alone or in combination, can alleviate neuropathic pain in CINP models. THC acts as a partial agonist at CB1 and CB2 receptors, while CBD has a more complex pharmacology, interacting with transient receptor potential (TRP) channels and other targets, and modulating endocannabinoid tone indirectly. The combination of the two has drawn particular interest because CBD may temper THC’s psychoactive effects while contributing its own analgesic and anti-inflammatory actions. Animal studies of paclitaxel-, oxaliplatin-, and cisplatin-induced neuropathy have reported reductions in mechanical and thermal hypersensitivity following cannabinoid treatment, in some cases with evidence of neuroprotection of sensory neurons in the dorsal root ganglia.

Yet the translation from bench to bedside has been disappointing. The review finds that clinical studies in patients with CINP have reported only modest or inconsistent benefits. Several factors may explain this translational gap. Preclinical models typically use fixed doses and formulations in young, otherwise healthy animals, whereas clinical trials must contend with heterogeneous patient populations, variable chemotherapy regimens, differing stages of neuropathy, and a wide range of cannabinoid products with uncertain composition and bioavailability. Dosing regimens that work in rodents may not map onto tolerable doses in humans, where psychoactive effects of THC and drug interactions with ongoing cancer therapy complicate escalation. The review underscores the need for rigorous preclinical characterization of phytocannabinoid formulations and dosing regimens precisely to bridge this gap—ensuring that the compounds, ratios, doses, and timing tested in animals are those most likely to succeed in the clinic.

The authors also emphasize the broader burden of CINP as a rationale for continued investment. Because the condition can compromise chemotherapy dosing, it affects not only quality of life but potentially oncological outcomes. A therapy that could prevent the onset of neuropathy—or reverse it once established—without interfering with chemotherapy’s anti-tumor efficacy would represent a significant advance. The endocannabinoid system’s position at the interface of neuronal and immune signaling makes it a plausible candidate for such dual protective and analgesic roles, and its modulation offers multiple pharmacological entry points, from enzyme inhibitors to receptor subtype-selective ligands that avoid central psychoactive effects by targeting peripheral CB1 or CB2 receptors.

In synthesizing the field, Soriano and Coronel aim to integrate current knowledge, highlight key translational gaps, and identify priorities for future research. Their critical appraisal makes clear that the story of cannabinoids and chemotherapy-induced neuropathic pain is neither one of simple promise nor of failure. The endocannabinoid system is genuinely dysregulated in experimental CINP, and manipulating it genuinely relieves pain-like behavior in animals. But the leap to effective, safe, and reproducible treatments for patients has not yet been made, and the clinical data that exist are too limited to support confident recommendations. The path forward, the review suggests, lies in better-controlled preclinical studies that mirror clinical conditions, carefully designed formulations and dosing strategies, and clinical trials rigorous enough to determine once and for all whether cannabinoid-based therapies can deliver on the promise that two decades of animal research has generated.

For now, patients and clinicians are left in an uncomfortable middle ground: a biological system with strong mechanistic credentials, a family of compounds with demonstrated preclinical efficacy, and a clinical evidence base that has not kept pace. As cannabis-derived medicines continue to attract public and scientific attention, this review serves as a sober reminder that enthusiasm must be matched by methodological rigor—and that the gap between what works in a mouse and what helps a patient remains one of the most important challenges in cannabinoid pain research.

Subject of Research: The role of the endocannabinoid system and cannabinoid-based therapies in chemotherapy-induced neuropathic pain, from preclinical promise to limited clinical evidence.

Article Title: The endocannabinoid system and cannabinoid-based therapies in chemotherapy-induced neuropathic pain: from preclinical promise to limited clinical evidence

Article References: Soriano, D., & Coronel, M. F. (2026). The endocannabinoid system and cannabinoid-based therapies in chemotherapy-induced neuropathic pain: from preclinical promise to limited clinical evidence. BMC Complementary Medicine and Therapies. https://doi.org/10.1186/s12906-026-05585-y

Image Credits: AI Generated

DOI: 10.1186/s12906-026-05585-y

Keywords: chemotherapy-induced neuropathic pain, endocannabinoid system, cannabinoid receptors, CB1, CB2, THC, cannabidiol, neuropathic pain, phytocannabinoids, allodynia, pain management, cancer survivors